Business Standard

Mumbai docs try Biocon and Roche's biologic drugs on critical Covid cases

Two repurposed drugs for rheumatoid arthritis and psoriasis are being tried on over 100 patients in Mumbai

Medics prepare before collecting samples for swab tests from a COVID-19 mobile testing van, during the nationwide lockdown to curb the spread of coronavirus, at Ramakrishna Mission area in New Delhi. (PTI Photo/Manvender Vashist)
Premium

Medics prepare before collecting samples for swab tests from a COVID-19 mobile testing van, during the nationwide lockdown to curb the spread of coronavirus, at Ramakrishna Mission area in New Delhi. (PTI Photo/Manvender Vashist)

Sohini DasSamreen Ahmad Mumbai/Bengaluru
Pharmaceutical giants Roche and Biocon have joined the race to roll out a drug to combat coronavirus. While Roche’s rheumatoid arthritis drug Actemra (tocilizumab), marketed by Cipla, is being tried to prevent extreme inflammation in gravely ill Covid-19 patients, Biocon is learnt to have been repurposing its psoriasis drug Itolizumab to treat the deadly virus.

The two biologic drugs are being tested on critically ill patients in Mumbai's Nair Hospital and King Edward Memorial (KEM) Hospital. Reports suggest that two patients at Nair Hospital, who were administered with Roche's Tocilizumab, have shown decent recovery and could be taken off ventilators.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in